DGAP-Adhoc: PAION AG GRANTS LICENSE TO R-PHARM FOR REMIMAZOLAM

PAION AG / Key word(s): Contract

30.10.2013 12:42

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

PAION AG GRANTS LICENSE TO R-PHARM FOR REMIMAZOLAM

- PAION will receive EUR 1 million upfront payment

- EUR 3.0 million regulatory and commercial milestone payments

- Exclusive license grant to R-Pharm in Russia and CIS

- Low double digit royalties

- Limited clinical bridging work in Russia needed

Aachen (Germany), 30 October 2013 - PAION AG (ISIN DE000A0B65S3; Frankfurt
Stock Exchange General Standard: PA8) and R-Pharm, Russia, today announced
that they have entered into a license agreement for Remimazolam which gives
R-Pharm an exclusive licence for the development, manufacture and
commercialization in the territory of Russia and CIS.

PAION will receive an upfront payment in the amount of EUR 1 million,
potential milestone payments of up to EUR 3 million and low double digit
royalties on net sales in the Territory.

R-Pharm will manage the development and marketing approval process in the
Territory. R-Pharm intends to market Remimazolam in all indications with
the lead indication anaesthesia and plans to start a bridging study in
anaesthesia as soon as possible.

###

Contact
Ralf Penner
Director Investor Relations / Public Relations
PAION AG
Martinstrasse 10-12
52062 Aachen - Germany
Phone: +49 241 4453-152
E-mail: r.penner@paion.com
www.paion.com

Eugenia Kasyanenko
PR-manager
R-Pharm
10, Testovskaya st., 123317, Moscow
Russian Federation
Phone: +7 (495) 956 79 37
E-Mail: kasyanenko@rpharm.ru
http://r-pharm.com/en/

Disclaimer:
This release contains certain forward-looking statements concerning the
future business of PAION AG. These forward-looking statements contained
herein are based on the current expectations, estimates and projections of
PAION AG's management as of the date of this release. They are subject to a
number of assumptions and involve known and unknown risks, uncertainties
and other factors. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ materially from any
future results and developments expressed or implied by such
forward-looking statements. Considering the risks, uncertainties and other
factors involved, recipients should not rely unreasonably upon these
forward-looking statements. PAION AG has no obligation to periodically
update any such forward-looking statements to reflect future events or
developments.

---------------------------------------------------------------------------

Language: English
Company: PAION AG
Martinstr. 10-12
52062 Aachen
Germany
Phone: +49 (0)241-4453-0
Fax: +49 (0)241-4453-100
E-mail: info@paion.com
Internet: www.paion.com
ISIN: DE000A0B65S3
WKN: A0B65S
Listed: Regulierter Markt in Frankfurt (General Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart

End of Announcement DGAP News-Service

---------------------------------------------------------------------------